Loading stock data…
NanoViricides (NNVC)
$1.37+0.03 (+2.24%)
Market ClosedLast close Jun 29
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NanoViricides, Inc. in the Healthcare sector is trading at $1.37 with a market capitalization of $30M. Wall Street consensus targets $6.00 (1 analysts), implying a +338.0% move over the next 12 months. The stock is currently 39% below its 52-week high of $2.23, remaining 6.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +338.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.03M↑ | -$2.23M↓ | -$1.80M↑ | -$2.12M↑ | -$2.25M |
| Net Income | -$1.99M↑ | -$2.22M↓ | -$1.79M↑ | -$2.10M↑ | -$2.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-88.39%
Volume
Today's trading volume
475,014
Recent News
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan
Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]
NanoViricides closes $2M direct offering
NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antiviral drug developer sold about 1.3 million shares of common stock, or pre-funded warrants in...
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak
NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of Ebola virus that has prompted the World Health Organisation to declare a global health emergency. The WHO designated the outbreak in...
NanoViricides to raise $2M in registered direct offering
NanoViricides (NYSE-A:NNVC) said it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately $2 million in a registered direct offering. Under the terms of the agreement, the company will sell just over 1.3 million common...
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs
By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the need for broad-spectrum antiviral drugs such as NV-387. The hantavirus gets into the lungs through droplets of cough or spit from an infected person and incidents are becoming more common on cruises, making a global […]